Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of LZ01 in treatment of Duchenne muscular dystrophy

A Duchenne muscular dystrophy and dystrophy technology, applied in the field of medicine, can solve problems such as no reports of LZ01 treating Duchenne muscular dystrophy, and achieve the effects of improving skeletal muscle pseudohypertrophy, muscle weight reduction, and reduced infiltration

Pending Publication Date: 2022-05-24
CHINA PHARM UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] LZ01 [1] (ZLY16) is a structural analogue of PPARα / δ agonist Elafibranor (GFT505), its structural formula is as follows figure 1 As shown, the search did not find any report on the treatment of Duchenne muscular dystrophy with LZ01

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of LZ01 in treatment of Duchenne muscular dystrophy
  • Application of LZ01 in treatment of Duchenne muscular dystrophy
  • Application of LZ01 in treatment of Duchenne muscular dystrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Pharmacodynamic evaluation of LZ01 in the treatment of muscle weakness and muscle atrophy in 3-4 weeks old mdx mice. Named as DMD model group, simvastatin treatment group and LZ01 treatment group, the doses of simvastatin treatment group and LZ01 treatment group were 20 mg / kg / day and 30 mg / kg / day, respectively. The specific groups and administration methods are shown in Table 1:

[0034] Table 1 Specific grouping of experimental mice, dosage and mode of administration

[0035]

[0036] Drugs were administered at 9-10 am every day, and all animal states were observed and recorded.

[0037] Muscle grasping force determination; for 3 weeks and 6 weeks after administration, the forelimb grasping force of mice was measured. The average value of each test was taken 3 times, and the results are shown in Table 2.

[0038] Table 2 Statistical results of muscle grip in mdx mice

[0039] grouping DMD model group LZ01 treatment group Simvastatin treatment gro...

Embodiment 2

[0043] Fasting after the last administration, the mdx mice in Example 1 were euthanized 24 hours later, blood was collected from the inguinal vein, centrifuged at 3500 rpm for 10 minutes, and the upper serum was taken to measure serum creatine kinase (CK) and lactate dehydrogenase (LDH) content. The gastrocnemius muscle (GAS), tibialis anterior muscle (TA), and diaphragm muscle (DIA) were then dissected and quickly frozen in liquid nitrogen, and then transferred to a -80°C refrigerator for use the next day. Serum CK, LDH content and skeletal muscle coefficient are shown in Table 3.

[0044] Table 3 mdx mouse skeletal muscle coefficient

[0045]

[0046]

[0047] * P<0.05 compared with DMD model group.

[0048] The results showed that after administration of LZ01, the content of serum creatine kinase tended to increase, but it had little effect on the content of LDH, and further research was needed. In addition, LZ01 had a tendency to reduce muscle weight in mdx mice,...

Embodiment 3

[0050] Hematoxylin-eosin (HE) staining was used to observe the pathological and morphological changes of skeletal muscle of each group of experimental mice in Example 3: fresh gastrocnemius muscle, tibialis anterior muscle and diaphragm muscle were quickly OCT embedded, and then sliced ​​in a cryostat. Each group of sections was stained with HE dye, and after mounting, the sections were observed and photographed under a microscope of model BX53 manufactured by Olympus in Japan. The result is as figure 2 shown.

[0051]The results showed that a large number of inflammatory cells were infiltrated in the tibialis anterior muscle and diaphragm muscle of the mice in the DMD model group, and the muscle fibers became rounded with different sizes, the nucleus was centralized, and the muscle fibers were obviously lost. LZ01 administration significantly increased the number of muscle fibers in the gastrocnemius, tibialis anterior and diaphragm muscles of mdx mice, and alleviated the n...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicines, and particularly relates to application of LZ01 in preparation of related medicines for treating Duchenne muscular dystrophy. The LZ01 finally improves myasthenia and / or amyotrophy caused by muscular dystrophy by relieving pseudoskeletal muscle hypertrophy, relieving muscle fiber necrosis and inflammatory cell infiltration, promoting muscle regeneration and relieving muscle fiber symptoms.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to the application of LZ01 in the preparation of medicines related to the treatment of Duchenne muscular dystrophy. Background technique [0002] Duchenne muscular dystrophy is a genetic disease caused by gene mutation. Gene therapy may eventually be an effective method for Duchenne muscular dystrophy, but so far, gene therapy methods are still in the research stage. The current first-line treatment for Duchenne muscular dystrophy is hormone combined nursing. Although hormone therapy has certain effects, it brings a series of adverse reactions to patients, including: gastrointestinal reactions, obesity, etc. Therefore, there is an urgent need to find drugs other than hormones to treat inflammation, oxidative stress and fibrosis in the muscle tissue of patients with Duchenne muscular dystrophy. [0003] LZ01 [1] (ZLY16) is a structural analog of PPARα / δ agonist Elafibranor (GFT505), whose s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/381A61K45/06A61P21/00
CPCA61K31/381A61K45/06A61P21/00A61K2300/00
Inventor 江振洲范书生陆茜俞沁玮张陆勇
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com